ELOS / Syneron Medical Ltd. - SEC Filings, Annual Report, Proxy Statement

Syneron Medical Ltd.
US ˙ NASDAQ
THIS SYMBOL IS NO LONGER ACTIVE

Basic Stats
CIK 1291361
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Syneron Medical Ltd.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
August 1, 2017 SC 13D/A

ELOS / Syneron Medical Ltd. / European High-tech Capital S.a. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Syneron Medical Ltd. (Name of Issuer) Ordinary Shares M87245102 (Title of Class of Securities) (CUSIP Number) European High-Tech Capital S.A. 52 Haag Street Haifa, Israel Telephone: +972-4-834-2928 (Name, Address and Telephone Number of Person Authorized to Receive Not

July 27, 2017 15-12G

Syneron Medical 15-12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50867 Syneron Medical Ltd. (Exact name of registrant as specified in its

July 17, 2017 S-8 POS

Syneron Medical S-8 POS

As filed with the Securities and Exchange Commission on July 17, 2017 Registration No.

July 17, 2017 S-8 POS

Syneron Medical S-8 POS

As filed with the Securities and Exchange Commission on July 17, 2017 Registration No.

July 17, 2017 S-8 POS

Syneron Medical S-8 POS

As filed with the Securities and Exchange Commission on July 17, 2017 Registration No.

July 17, 2017 S-8 POS

Syneron Medical S-8 POS

As filed with the Securities and Exchange Commission on July 17, 2017 Registration No.

July 17, 2017 S-8 POS

Syneron Medical S-8 POS

As filed with the Securities and Exchange Commission on July 17, 2017 Registration No.

July 17, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

6-K 1 zk1720262.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 17, 2017 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant's name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executi

July 7, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / BRANDES INVESTMENT PARTNERS, LP - SC 13G/A Passive Investment

Page 1 of 9 OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: August 31,1999 Washington, D.

June 15, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 15, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

May 30, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / North Tide Capital Master, LP - AMENDMENT NO. 5 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SYNERON MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) May 26, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

May 23, 2017 SD

Syneron Medical SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Syneron Medical Ltd. (Exact name of registrant as specified in charter) Israel (State or other jurisdiction of incorporation or organization) 001-34559 (Commission File Number) N/A (IRS Employer Identification No.) Industrial Zone, Tavor Building P.O.B. 550, Yokneam Illit 2069200, Israel (

May 23, 2017 EX-1.01

Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2016

Exhibit 1.01 Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2016 This report for the year ended December 31, 2016 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the " Rule"). The Rule was adopted by the Securities and Exchange Commission (the " SEC") to implement reporting and disclosure requirements related to conflict minerals as

May 18, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 17, 2017 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 15, 2017 EX-99.2

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

Exhibit 99.2 SYNERON MEDICAL LTD. ATTN: HUGO GOLDMAN, CFO INDUSTRIAL ZONE TAVOR BDG P.O.B. 550 YOKNEAM ILLIT, 20692 ISRAEL VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on June 14, 2017. Have your proxy card in hand when you access the web site and follow the instructions to obt

May 15, 2017 EX-99.1

SYNERON MEDICAL LTD.

Exhibit 99.1 SYNERON MEDICAL LTD. May 12 , 2017 To the Shareholders of Syneron Medical Ltd.: You are cordially invited to attend the Special General Meeting of Shareholders (which we refer to as the Meeting) of Syneron Medical Ltd. (which we refer to as Syneron or the Company) to be held at our executive offices located at Industrial Zone, Tavor Building, P.O.B. 550, Yokneam Illit 20692, Israel on

May 15, 2017 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 15, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translat

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 15, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 11, 2017 SC 13D/A

ELOS / Syneron Medical Ltd. / Sand Grove Capital Management LLP - SYNERON MEDICAL LTD SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* SYNERON MEDICAL LTD (Name of Issuer) Common Stock (Title of Class of Securities) M87245102 (CUSIP Number) Jonathan Groom 4th floor, 35 Dover Street London W1S 4NQ +44 (0) 203 770 8613 (Name, Address and Telephone Number of Person Authorized to Receive No

May 10, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 10, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 10, 2017 SC 13D

ELOS / Syneron Medical Ltd. / Sand Grove Capital Management LLP - SYNERON MEDICAL LTD SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* SYNERON MEDICAL LTD (Name of Issuer) Common Stock (Title of Class of Securities) M87245102 (CUSIP Number) Jonathan Groom 4th floor, 35 Dover Street London W1S 4NQ +44 (0) 203 770 8613 (Name, Address and Telephone Number of Person Authorized to Receive Not

May 1, 2017 EX-99.2

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.2 SYNERON MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS I, the undersigned shareholder of Syneron Medical Ltd. (the "Company"), do hereby nominate, constitute and appoint Mr. Hugo Goldman, Ms. Shir Kligler, and Ms. Terry Gerstner, or any one of them, my true and lawful proxy and attorney(s) with full power of substitution for me and in my name, place and stead

May 1, 2017 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 1, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translati

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 1, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by ch

May 1, 2017 EX-99.1

SYNERON MEDICAL LTD.

Exhibit 99.1 SYNERON MEDICAL LTD. , 2017 To the Shareholders of Syneron Medical Ltd.: You are cordially invited to attend the Special General Meeting of Shareholders (which we refer to as the Meeting) of Syneron Medical Ltd. (which we refer to as Syneron or the Company) to be held at our executive offices located at Industrial Zone, Tavor Building, P.O.B. 550, Yokneam Illit 20692, Israel on Thursd

April 19, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / Senvest Management, LLC - SENVEST MANAGEMENT, LLC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Syneron Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) April 3, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

April 10, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 10, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

April 10, 2017 EX-99.1

SYNERON MEDICAL LTD. Tavor Building, Yokneam Industrial Zone, Yokneam Illit 20692, Israel NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS To Be Held on June 15, 2017

Exhibit 99.1 SYNERON MEDICAL LTD. Tavor Building, Yokneam Industrial Zone, Yokneam Illit 20692, Israel NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS To Be Held on June 15, 2017 The Special General Meeting of shareholders of Syneron Medical Ltd., a company organized under the laws of the State of Israel (the ? Company?), will be held at the offices of the Company located at the Tavor Building,

April 10, 2017 EX-99.2

SYNERON MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 Exhibit 99.2 SYNERON MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS I, the undersigned shareholder of Syneron Medical Ltd. (the "Company"), do hereby nominate, constitute and appoint Mr. Hugo Goldman, Ms. Shir Kligler, and Ms. Terry Gerstner, or any one of them, my true and lawful proxy and attorney(s) with full power of substitution

April 3, 2017 EX-99.1

AGREEMENT AND PLAN OF MERGER BY AND AMONG LUPERT LTD., RENDEL AMARE LTD., SYNERON MEDICAL LTD. DATED AS OF APRIL 2, 2017

Exhibit 99.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG LUPERT LTD., RENDEL AMARE LTD., AND SYNERON MEDICAL LTD. DATED AS OF APRIL 2, 2017 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1. The Merger 2 1.2. Closing of the Merger 2 1.3. Effective Time 2 1.4. Effects of the Merger 3 1.5. Articles of Association 3 1.6. Board of Directors 3 1.7. Officers 3 ARTICLE II CONSIDERATION 3

April 3, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 3, 2017 Commission File Number: 000-50867 SYNERON MEDICAL LTD. (Translation of registrant’s name into English) Industrial Zone, Tavor Building P.O.B. 550, Yokneam Illit 20692, Israel (Address of principal executive office

April 3, 2017 EX-99.3

Syneron Candela Announces Agreement to be Acquired by Funds advised by Apax Partners for $11.00/share in Cash, Representing an Approximate Value of $397 Million

Exhibit 99.3 Syneron Candela Announces Agreement to be Acquired by Funds advised by Apax Partners for $11.00/share in Cash, Representing an Approximate Value of $397 Million Irvine, CA and London, April 3, 2017 ? Syneron Medical Ltd. (NASDAQ: ELOS), a leading global non-surgical aesthetic device company, and Apax Partners, a leading global private equity advisory firm, today announced a definitive

April 3, 2017 EX-99.2

VOTING AGREEMENT

EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 Exhibit 99.2 Execution Version VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of April 2, 2017 by and between among Lupert Ltd., a company organized under the Laws of the State of Israel (“Parent”) and Shimon Eckhouse (the “Shareholder”), who holds 2,689,911 Ordinary Shares (and 281,250 Ordinary Shares issuable upon exer

March 27, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 27, 2017 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 23, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 23, 2017 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant's name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 23, 2017 EX-12.A1

CERTIFICATION

EXHIBIT 12.(a)(1) CERTIFICATION I, Amit Meridor, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

March 23, 2017 EX-4.21

SHARE PURCHASE AGREEMENT BY AND AMONG A COMPANY IN FORMATION UNDER ISRAELI LAW., LIGHT INSTRUMENTS LTD., SYNERON MEDICAL LTD., Dated as of February 22, 2016 TABLE OF CONTENTS

Exhibit 4.21 Execution Version SHARE PURCHASE AGREEMENT BY AND AMONG A COMPANY IN FORMATION UNDER ISRAELI LAW., LIGHT INSTRUMENTS LTD., AND SYNERON MEDICAL LTD., Dated as of February 22, 2016 TABLE OF CONTENTS Page Article 1 DEFINITIONS 4 1.1 Defined Terms 4 1.2 Additional Defined Terms 7 1.3 Interpretation 8 Article 2 PURCHASE OF Shares 9 2.1 Purchase and Sale of Shares. 9 2.2 Purchase Price. 9 2

March 23, 2017 EX-15.A1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.(a).1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-120559, 333-164250, 333-164351, 333-192729, and 213539) pertaining to the equity incentive plans and share option plans of Syneron Medical Ltd. of our reports, dated March , 2017, with respect to the consolidated financial state

March 23, 2017 EX-13.A1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.(a).1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Syneron Medical Ltd. (the "Company") on Form 20-F for the period ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to our kno

March 23, 2017 EX-12.A2

CERTIFICATION

EXHIBIT 12.(a)(2) CERTIFICATION I, Hugo Goldman, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

March 23, 2017 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

March 8, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 8, 2016 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant's name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 8, 2017 EX-99

JOINT CONTRIBUTION AGREEMENT

EXHIBIT 4.20 EXECUTION VERSION THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. JOINT CONTRIBUTION AGREEMENT THIS JOINT CONTRIBUTION AGREEMENT (the " Agreement") is made as of November 8, 2013, by and among: (i) SYNERON MEDICAL L

February 15, 2017 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

6-K 1 zk1719565.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 15, 2017 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal exe

February 15, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / Visium Asset Management, LP - AMENDMENT TO FORM SC13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Syneron Medical Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file

February 14, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / North Tide Capital Master, LP - AMENDMENT NO. 4 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* SYNERON MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) Dec

February 13, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / Senvest Management, LLC - SYNERON MEDICAL LTD. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Syneron Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

January 10, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / BRANDES INVESTMENT PARTNERS, LP - SC 13G/A Passive Investment

OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: August 31,1999 Washington, D.

January 6, 2017 SC 13G/A

ELOS / Syneron Medical Ltd. / DRILL CRAIG A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

November 9, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

6-K 1 zk1619164.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 9, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal exec

November 8, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 8, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 8, 2016 SC 13G/A

ELOS / Syneron Medical Ltd. / BRANDES INVESTMENT PARTNERS, LP - SC 13G/A Passive Investment

Page 1 of 9 OMB APPROVAL OMB Number: 3235-0145 Expires: August 31,1999 Estimated average burden hours per response.

October 17, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 17, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

October 17, 2016 SC 13G

ELOS / Syneron Medical Ltd. / DRILL CRAIG A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

September 21, 2016 CORRESP

Syneron Medical ESP

September 21, 2016 Mr. Martin James, Senior Assistant Chief Accountant Office of Electronics and Machinery Division of Corporation Finance, Mail Stop 3030 100 F Street, N.E. Washington, D.C. 20549 Re: Syneron Medical Ltd. Form 20-F for the fiscal year ended December 31, 2015 Filed March 21, 2016 Form 6-K filed August 11, 2016 File No. 001-34559 Dear Mr. James: We are responding to your letter date

September 13, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 13, 2016 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicat

September 8, 2016 S-8

Syneron Medical S-8

zk1618989.htm Registration No. 333 - As filed with the Securities and Exchange Commission on September 8, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYNERON MEDICAL LTD. (Exact name of Registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or Organization) Not Ap

September 8, 2016 SC 13G/A

ELOS / Syneron Medical Ltd. / JP Morgan Chase & Co Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(c) ( AMENDMENT 5) SYNERON MEDICAL LTD.

August 16, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

6-K 1 zk1618829.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 16, 2016 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal execu

August 16, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

6-K 1 zk1618829.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 16, 2016 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal execu

August 11, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 11, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

August 11, 2016 CORRESP

Syneron Medical ESP

August 11, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

July 26, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 26, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 20, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 20, 2016 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 18, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

6-K 1 zk1618724.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 18, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executi

May 31, 2016 SD

Syneron Medical SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Syneron Medical Ltd. (Exact name of registrant as specified in charter) Israel (State or other jurisdiction of incorporation or organization) 001-34559 (Commission File Number) N/A (IRS Employer Identification No.) Industrial Zone, Tavor Building P.O.B. 550, Yokneam Illit 20692, Israel (Ad

May 31, 2016 EX-1.01

Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2015

EX-1.01 2 exhibit1-01.htm EXHIBIT 1.01 Exhibit 1.01 Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2015 This report for the year ended December 31, 2015 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). The Rule was adopted by the Securities and Exchange Commission (the "SEC") to implement reporting and disclosure requirem

May 23, 2016 SC 13G

ELOS / Syneron Medical Ltd. / Camber Capital Management LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Syneron Medical LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) May 13, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic

May 23, 2016 EX-1

JOINT FILING AGREEMENT

EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated May 23, 2016 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").

May 20, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1618544.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 20, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices)

March 23, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 23, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 21, 2016 EX-13.A1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.(a).1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Syneron Medical Ltd. (the "Company") on Form 20-F for the period ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to our kno

March 21, 2016 EX-15.A1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.(a).1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-120559, 333-164250, 333-164351 and 333-192729) pertaining to the equity incentive plans and share option plans of Syneron Medical Ltd. of our reports, dated March 21, 2016, with respect to the consolidated financial statements o

March 21, 2016 EX-12.A2

CERTIFICATION

Exhibit 12.(a)(2) CERTIFICATION I, Hugo Goldman, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

March 21, 2016 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

March 21, 2016 EX-12.A1

CERTIFICATION

Exhibit 12.(a)(1) CERTIFICATION I, Amit Meridor, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

February 22, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1618109.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 22, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive off

February 16, 2016 SC 13G/A

ELOS / Syneron Medical Ltd. / North Tide Capital Master, LP - AMENDMENT NO. 3 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SYNERON MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) Dec

February 16, 2016 SC 13G/A

ELOS / Syneron Medical Ltd. / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

February 12, 2016 SC 13G/A

Syneron Medical SENVEST MANAGEMENT, LLC (Passive Acquisition of More Than 5% of Shares)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Syneron Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

February 12, 2016 SC 13G/A

Syneron Medical AMENDMENT NO.4 TO SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

Amendment No.4 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Syneron Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

February 3, 2016 SC 13G/A

ELOS / Syneron Medical Ltd. / BRANDES INVESTMENT PARTNERS, LP - SC 13G/A Passive Investment

Page 1 of 10 OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: August 31,1999 Washington, D.

January 11, 2016 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1617842.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 11, 2016 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offi

November 16, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

6-K 1 zk1517578.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 13, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal exe

November 12, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1517576.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 12, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive off

October 26, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1517449.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 26, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offi

August 4, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1517156.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 4, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive office

July 27, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1517097.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 27, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices

June 25, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516988.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 25, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices

June 24, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516984.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 24, 2015 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices

June 4, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516912.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 4, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices)

June 2, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516851.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 3, 2015 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices)

June 1, 2015 EX-1.01

Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2014

Unassociated Document Exhibit 1.01 Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2014 This report for the year ended December 31, 2014 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). The Rule was adopted by the Securities and Exchange Commission (the "SEC") to implement reporting and disclosure requirements related to c

June 1, 2015 SD

Syneron Medical

Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

May 26, 2015 SC 13G

ELOS / Syneron Medical Ltd. / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

May 14, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516780.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 14, 2015 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices)

May 13, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516767.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 13, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices)

April 29, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516658.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 29, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive office

April 20, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516606.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 20, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive office

March 25, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516501.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 25, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive office

March 24, 2015 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

March 24, 2015 EX-12.A2

CERTIFICATION

EXHIBIT 12.(a)(2) CERTIFICATION I, Hugo Goldman, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

March 24, 2015 EX-12.A1

CERTIFICATION

EXHIBIT 12.(a)(1) CERTIFICATION I, Amit Meridor, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

March 24, 2015 EX-13.A1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.(a).1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Syneron Medical Ltd. (the "Company") on Form 20-F for the period ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to our kno

March 24, 2015 EX-15.A1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.(a).1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-120559, 333-164250, 333-164351 and 333-192729) pertaining to the equity incentive plans and share option plans of Syneron Medical Ltd. of our reports, dated March 24, 2015, with respect to the consolidated financial statements o

March 23, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516482.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 23, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive office

March 5, 2015 6-K

Syneron Medical 6-K (Current Report of Foreign Issuer)

zk1516387.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 5, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices

February 23, 2015 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 23, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

February 17, 2015 SC 13G/A

ELOS / Syneron Medical Ltd. / Senvest Management, LLC - RIMA SENVEST MANAGEMENT, LLC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Syneron Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

February 13, 2015 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 13, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

February 13, 2015 SC 13G/A

ELOS / Syneron Medical Ltd. / North Tide Capital Master, LP - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SYNERON MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) Dec

February 12, 2015 SC 13G/A

ELOS / Syneron Medical Ltd. / Visium Asset Management, LP - SC 13G/A Passive Investment

SC 13G/A 1 d871554dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Syneron Medical Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

February 11, 2015 SC 13G/A

ELOS / Syneron Medical Ltd. / BRANDES INVESTMENT PARTNERS, LP - SC 13G/A Passive Investment

OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: August 31,1999 Washington, D.

February 10, 2015 SC 13G/A

ELOS / Syneron Medical Ltd. / Baupost Group LLC/MA - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Syneron Medical, Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) M87245102 (CUSIP Number) January 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

February 5, 2015 CORRESP

ELOS / Syneron Medical Ltd. CORRESP - -

Tel Aviv, February 5, 2015 Via Edgar Mr. Martin James Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: Syneron Medical Ltd. Form 20-F Filed March 19, 2014 File No. 1-34559 Dear Mr. James: We enclose a response to Comment 3 raised by the staff of the Securities and Exchange Commission (the “Staff”) in its comment letter,

February 5, 2015 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 5, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

February 5, 2015 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 5, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

January 30, 2015 CORRESP

ELOS / Syneron Medical Ltd. CORRESP - -

Tel Aviv, January 30, 2015 Via Edgar Mr. Martin James Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: Syneron Medical Ltd. Form 20-F Filed March 19, 2014 File No. 1-34559 Dear Mr. James: We enclose responses to the comments raised by the staff of the Securities and Exchange Commission (the “Staff”) in its comment lette

January 12, 2015 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 12, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

January 8, 2015 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 8, 2015 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

December 8, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 8, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

December 1, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 1, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 18, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 18, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 14, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 14, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 12, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 12, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

October 24, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 24, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

October 9, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 8, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

August 14, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 14, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

August 6, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 6, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 29, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 29, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 22, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 22, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 21, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 21, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 17, 2014 6-K

ELOS / Syneron Medical Ltd. 6-K - Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 15, 2014 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

June 17, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 17, 2014 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

June 2, 2014 EX-1.01

Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2013

Exhibit 1.01 Syneron Medical Ltd. Conflict Minerals Report For The Year Ended December 31, 2013 This report for the year ended December 31, 2013 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (the SEC) to implement reporting and disclosure requirements related to conflict minerals as direct

June 2, 2014 SD

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Syneron Medical Ltd. (Exact name of registrant as specified in charter) Israel (State or other jurisdiction of incorporation or organization) 001-34559 (Commission File Number) N/A (IRS Employer Identification No.) Industrial Zone, Tavor Building P.O.B. 550, Yokneam Illit 20692, Israel (Ad

June 2, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 2, 2014 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 30, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 30, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 14, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 14, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

April 24, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 24, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

April 14, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 14, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 24, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 24, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 19, 2014 EX-15.A1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

EXHIBIT 15.(a)(1) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-120559, 333-164250, 333-164351 and 333-192729) pertaining to the equity incentive plans and share option plans of Syneron Medical Ltd. of our reports, dated March 19, 2014, with respect to the consolidated financial statements

March 19, 2014 EX-13.A1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.(a).1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Syneron Medical Ltd. (the "Company") on Form 20-F for the period ended December 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to our kno

March 19, 2014 20-F

- 20-F

20-F 1 zk1414596.htm 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

March 19, 2014 EX-4.20

JOINT CONTRIBUTION AGREEMENT

EXHIBIT 4.20 EXECUTION VERSION THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. JOINT CONTRIBUTION AGREEMENT THIS JOINT CONTRIBUTION AGREEMENT (the “Agreement”) is made as of November 8, 2013, by and among: (i) SYNERON MEDICAL LT

March 19, 2014 EX-4.21

AGREEMENT AND PLAN OF MERGER by and among SYNERON, INC. a corporation organized under the laws of the State of Delaware; CTRIA ACQUISITION CORPORATION; and NEW STAR LASERS, INC. a corporation organized under the laws of the State of California; d.b.a

EX-4.21 3 exhibit4-21.htm EXHIBIT 4.21 EXHIBIT 4.21 Execution Version THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AGREEMENT AND PLAN OF MERGER by and among SYNERON, INC. a corporation organized under the laws of the State of

March 19, 2014 EX-12.A1

CERTIFICATION

EXHIBIT 12.(a).(1) CERTIFICATION I, Amit Meridor, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp

March 19, 2014 EX-12.A2

CERTIFICATION

EXHIBIT 12.(a).(2) CERTIFICATION I, Hugo Goldman, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp

March 4, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 4, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

February 24, 2014 SC 13G/A

ELOS / Syneron Medical Ltd. / Senvest Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

February 20, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 20, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

February 20, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 20, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

February 14, 2014 SC 13G/A

ELOS / Syneron Medical Ltd. / Visium Asset Management, LP - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Syneron Medical Ltd (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

February 14, 2014 SC 13G/A

ELOS / Syneron Medical Ltd. / NORTH TIDE CAPITAL, LLC - AMEND NO.1 TO SCHEDULE 13G (FEB 2014) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SYNERON MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t

February 13, 2014 SC 13G/A

ELOS / Syneron Medical Ltd. / Senvest Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

February 10, 2014 SC 13G

ELOS / Syneron Medical Ltd. / BRANDES INVESTMENT PARTNERS, LP - SC 13G Passive Investment

SC 13G 1 v367813sc13-g.htm SC 13G Page 1 of 10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) * Syneron Medical Ltd. (Name of Issuer) Common Shares (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

February 5, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 5, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

January 28, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 27, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

January 15, 2014 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 15, 2014 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

December 19, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 19, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

December 9, 2013 S-8

- S-8

Registration No. 333 - As filed with the Securities and Exchange Commission on December 9, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYNERON MEDICAL LTD. (Exact name of Registrant as specified in its charter) Israel Not Applicable (State or other jurisdiction of (IRS Employer incorporation or Organi

December 9, 2013 EX-99.1

SYNERON BEAUTY LTD. 2011 SHARE OPTION PLAN

EX-99.1 4 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 SYNERON BEAUTY LTD. 2011 SHARE OPTION PLAN 1. Purpose. The purpose of this Share Option Plan (the “Plan”) is to advance the interests of Syneron Beauty Ltd. (the “Company”) and its shareholders by attracting and retaining the best available personnel for positions of substantial responsibility, providing additional incentive to employees, officer

December 9, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 9, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

December 9, 2013 EX-99.2

Syneron Beauty LTD. 2011 Equity Incentive Plan – United States

EXHIBIT 99.2 Syneron Beauty LTD. 2011 Equity Incentive Plan – United States This plan, as amended from time to time, shall be known as the Syneron Beauty Ltd. 2011 Equity Incentive Plan – United States. The Plan is intended to provide an incentive to retain in the employ of the Company (as defined below) and its Subsidiaries (as defined below), persons of training, experience and ability; to attra

November 13, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 13, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 12, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 11, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 12, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 11, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 8, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 8, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, YokneamIllit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

October 21, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 21, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

September 26, 2013 SC 13G

ELOS / Syneron Medical Ltd. / NORTH TIDE CAPITAL, LLC - SCHEDULE 13G (SEPT 2013) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SYNERON MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M87245102 (CUSIP Number) Sept

September 26, 2013 EX-99.1

JOINT FILING AGREEMENT

EX-99.1 2 northsyneron-ex991.htm JOINT FILER AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of September 26, 2013 is by and among North Tide Capital Master, LP, North Tide Capital, LLC and Conan Laughlin, an individual (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securitie

September 11, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 11, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicat

August 14, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 14, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

August 7, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 7, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 25, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 25, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 18, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 18, 2013 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 10, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 10, 2013 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

June 20, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 19, 2013 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

June 17, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 3, 2013 Commission File Number: 001-34559 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 23, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 22, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 16, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 15, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 2, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 2, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by ch

April 18, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 18, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

April 17, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 17, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

April 4, 2013 6-K

Current Report of Foreign Issuer - CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 4, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 25, 2013 EX-99.1

Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website

Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website Yokneam Illit, Israel, March 21, 2013 – Syneron Medical Ltd. (Nasdaq: ELOS), the leading global aesthetic device company, today announced that its Annual Report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2012, as filed with the Securities and Exc

March 25, 2013 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 25, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

March 21, 2013 EX-13.A-1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.(a).1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Syneron Medical Ltd. (the "Company") on Form 20-F for the period ended December 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to our kno

March 21, 2013 EX-12.A-2

CERTIFICATION

EXHIBIT 12.(a)(2) CERTIFICATION I, Hugo Goldman, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

March 21, 2013 EX-4.20

SHARE PURCHASE AGREEMENT BY AND AMONG RAKUTO BIO TECHNOLOGIES LTD., SYNERON MEDICAL LTD., THE SELLERS SET FORTH ON THE SIGNATURES PAGES HERETO MR. HAIM LASSER, AS THE SELLERS' REPRESENTATIVE Dated as of May 30, 2012 TABLE OF CONTENTS

Exhibit 4.20 Execution Verion SHARE PURCHASE AGREEMENT BY AND AMONG RAKUTO BIO TECHNOLOGIES LTD., SYNERON MEDICAL LTD., THE SELLERS SET FORTH ON THE SIGNATURES PAGES HERETO AND MR. HAIM LASSER, AS THE SELLERS' REPRESENTATIVE Dated as of May 30, 2012 TABLE OF CONTENTS Page Article 1 DEFINITIONS 5 1.1 Defined Terms 5 1.2 Additional Defined Terms 9 1.3 Interpretation 10 Article 2 PURCHASE OF Shares 1

March 21, 2013 EX-15.A-1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.(a).1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-120559, 333-164250 and 333-164351) pertaining to the Stock Option Plans of Syneron Medical Ltd. of our reports dated March 21, 2013, with respect to the consolidated financial statements of Syneron Medical Ltd. for the year ende

March 21, 2013 EX-12.A-1

CERTIFICATION

EXHIBIT 12.(a)(1) CERTIFICATION I, Louis Scafuri, certify that: 1. I have reviewed this Annual Report on Form 20-F of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp

March 21, 2013 20-F

- 20-F

20-F 1 zk1312805.htm 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

February 22, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 21, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

February 22, 2013 EX-99.1

Syneron Settles U.S. Patent Infringement Lawsuit with EndyMed and Eclipse Aesthetics

EX-99.1 2 v335915ex99-1.htm EXHIBIT 99.1 Syneron Settles U.S. Patent Infringement Lawsuit with EndyMed and Eclipse Aesthetics YOKNEAM, Israel, Feb. 21, 2013 /PRNewswire/ - Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company announced today, jointly with EndyMed Medical Ltd. and Eclipse Aesthetics, that Syneron has dismissed its United States patent infringement lawsuit

February 14, 2013 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 12, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

February 14, 2013 SC 13G/A

ELOS / Syneron Medical Ltd. / Visium Asset Management, LP - SCHEDULE 13G (AMENDMENT NO. 1) Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Syneron Medical Ltd (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) M87245102 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

February 14, 2013 EX-99.1

Syneron Reports Fourth Quarter and Full Year 2012 Results Record quarterly revenue of $72.8 million, up 19% y/y Non-GAAP Q4: Operating margin more than doubles to 7.8%; Net income of $4.1 million, or $0.11 per share, up from $1.1 million; Cash from o

EX-99.1 2 v334733ex99-1.htm EXHIBIT 99.1 Syneron Reports Fourth Quarter and Full Year 2012 Results Record quarterly revenue of $72.8 million, up 19% y/y Non-GAAP Q4: Operating margin more than doubles to 7.8%; Net income of $4.1 million, or $0.11 per share, up from $1.1 million; Cash from operations of $8.8 million Yokneam, Israel, February 12, 2013 – Syneron Medical Ltd. (NASDAQ:ELOS), the leadin

February 14, 2013 SC 13G

ELOS / Syneron Medical Ltd. / Senvest Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

January 30, 2013 EX-99.1

Syneron Medical to Report Fourth Quarter and Full Year 2012 Financial Results on February 12, 2013

Syneron Medical to Report Fourth Quarter and Full Year 2012 Financial Results on February 12, 2013 YOKNEAM, Israel, Jan.

January 30, 2013 6-K

Current Report of Foreign Issuer - CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 29, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

January 17, 2013 SC 13G/A

ELOS / Syneron Medical Ltd. / JPMORGAN CHASE & CO - SYNERON MEDICAL LTD. SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) ( AMENDMENT 1) Syneron Medical Ltd.

January 4, 2013 EX-99.1

Syneron to Present at 15th Annual Needham Growth Conference

EX-99.1 2 v331395ex99-1.htm EXHIBIT 99.1 Syneron to Present at 15th Annual Needham Growth Conference YOKNEAM, Israel, Jan. 4, 2013 /PRNewswire/ - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that Louis P. Scafuri, Chief Executive Officer, is scheduled to present at the 15th Annual Needham Growth Conference in New York City. (Logo: http://photos.

January 4, 2013 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 4, 2013 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

November 19, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 12, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant?s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 19, 2012 EX-99.1

Syneron Medical Announces Death of Longtime Board Member Marshall D. Butler

EX-99.1 2 v328596ex99-1.htm EXHIBIT 99.1 Syneron Medical Announces Death of Longtime Board Member Marshall D. Butler YOKNEAM, Israel, Nov. 12, 2012 /PRNewswire/ - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced the death of Marshall D. Butler, member of the Company's Board of Directors since 2003. (Logo: http://photos.prnewswire.com/prnh/20120528/535447)

November 19, 2012 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 15, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 19, 2012 EX-99.1

Syneron to Participate in Two Upcoming Investor Conferences

Syneron to Participate in Two Upcoming Investor Conferences YOKNEAM, Israel, Nov. 15, 2012 /PRNewswire/ - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that Company management is scheduled to participate at two upcoming investor conferences. (Logo: http://photos.prnewswire.com/prnh/20120528/535447) The first conference is the Leerink Swann Novemb

November 7, 2012 EX-99.1

Syneron Medical Appoints Hugo Goldman as Chief Financial Officer

EX-99.1 2 v327684ex99-1.htm EXHIBIT 99.1 Syneron Medical Appoints Hugo Goldman as Chief Financial Officer Yokneam, Israel – November 5, 2012 – Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the leading global aesthetic device company, announced today that Hugo Goldman has been appointed Chief Financial Officer, effective immediately. Mr. Goldman replaces David Schlachet, who had been servin

November 7, 2012 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 5, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 7, 2012 EX-99.1

Syneron Medical Appoints Jonathan Pearson as Executive Vice President of Business Development, Topical Products

Syneron Medical Appoints Jonathan Pearson as Executive Vice President of Business Development, Topical Products Yokneam, Israel – November 7, 2012 – Syneron Medical Ltd.

November 7, 2012 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 7, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 7, 2012 6-K

Current Report of Foreign Issuer - 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 7, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

November 7, 2012 EX-99.1

Syneron Reports Third Quarter 2012 Results Revenue of $60.1 million, up 6% Year-Over-Year Improved gross margins

Syneron Reports Third Quarter 2012 Results Revenue of $60.1 million, up 6% Year-Over-Year Improved gross margins Yokneam, Israel, November 7, 2012– Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, today announced third quarter 2012 financial results for the three month and nine month periods ended September 30, 2012. Third Quarter 2012 Year-Over-Year Financial Highl

November 5, 2012 EX-99.1

Syneron Highlights its Innovative Body Shaping Products

Syneron Highlights its Innovative Body Shaping Products in Conjunction with the BODY Conference and Exhibition in London London, United Kingdom, November 5, 2012 – Syneron Medical Ltd.

November 5, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 5, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

October 22, 2012 EX-99.1

Syneron Announces Availability of elōs Plus™ in Canada Following Health Canada Clearance

EX-99.1 2 v326079ex99-1.htm EXHIBIT 99.1 Syneron Announces Availability of elōs Plus™ in Canada Following Health Canada Clearance Yokneam, Israel – October 22, 2012 – Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the leading global aesthetic device company, announced today Health Canada clearance and the commercial launch of the elōs Plus™ next generation multi-platform system in Canada. T

October 22, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 22, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

October 18, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 18, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate

October 18, 2012 EX-99.1

Syneron Receives FDA Clearance for “mē” Home-Use Hair Removal System First and only FDA cleared home-use hair removal device approved for all skin tones

EX-99.1 2 v326080ex99-1.htm EXHIBIT 99.1 Syneron Receives FDA Clearance for “mē” Home-Use Hair Removal System First and only FDA cleared home-use hair removal device approved for all skin tones Yokneam, Israel, October 18, 2012 – Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the leading global aesthetic device company, announced today that it has received 510(k) clearance from the United S

October 9, 2012 EX-99.1

Syneron Honors Company Founder and IPL Inventor Shimon Eckhouse at Gala Dinner at the 2012 EADV Congress

EX-99.1 2 v325279ex99-1.htm EXHIBIT 99.1 Syneron Honors Company Founder and IPL Inventor Shimon Eckhouse at Gala Dinner at the 2012 EADV Congress YOKNEAM, Israel, Oct. 3, 2012 /PRNewswire/ - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, honored Dr. Shimon Eckhouse, its founder and the inventor of IPL (Intense Pulsed Light), at a gala dinner held during the EADV

October 9, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 4, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

October 9, 2012 EX-99.1

Syneron Highlights New Products at IMCAS Asia Meeting

Syneron Highlights New Products at IMCAS Asia Meeting Includes Introduction of High-Energy eTwo System and Recently Launched Gentle Pro-U Series and elos Plus System YOKNEAM, Israel, Oct.

October 9, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 3, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

October 2, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 27, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicat

September 27, 2012 EX-12.(A)(1)

CERTIFICATION

EXHIBIT 12.(a)(1) CERTIFICATION I, Louis Scafuri, certify that: 1. I have reviewed this Annual Report on Form 20-F/A of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re

September 27, 2012 EX-12.(A)(2)

CERTIFICATION

EXHIBIT 12.(a)(2) CERTIFICATION I, David Schlachet, certify that: 1. I have reviewed this Annual Report on Form 20-F/A of Syneron Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with

September 27, 2012 EX-13.(A)(1)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.(a).1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Syneron Medical Ltd. (the "Company") on Form 20-F/A for the period ended December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to our k

September 27, 2012 20-F/A

- 20 F/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR

September 27, 2012 EX-15.(A)(1)

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.(a).(1) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-120559, 333-164250 and 333-164351) pertaining to the Stock Option Plans of Syneron Medical Ltd. of our reports dated March 29, 2012, except for Note 2(v) and Note 15(12), as to which the date is September 27, 2012, with respec

September 20, 2012 6-K/A

Current Report of Foreign Issuer - AMENDMENT TO FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 20, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal execut

September 19, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 19, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicat

September 14, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 11, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicat

September 14, 2012 EX-99.1

Syneron to Participate in Two Upcoming Investor Conferences

Syneron to Participate in Two Upcoming Investor Conferences Yokneam, Israel, September 11, 2012 – Syneron Medical Ltd.

September 12, 2012 CORRESP

-

Tel Aviv, September 12, 2012 Via Edgar Mr. Kevin L. Vaughn Accounting Branch Chief Securities and Exchange Commission Washington , D.C. 20549 Re: Syneron Medical Ltd. Form 20-F for the Fiscal Year Ended December 31, 2011 Filed March 29, 2012 File No. 0-50867 Dear Mr. Vaughn: We enclose responses to the comments raised by the staff of the Securities and Exchange Commission (the “Staff”) in its comm

August 28, 2012 CORRESP

-

August 28, 2012 Via E-mail Mr. Kevin L. Vaughn Accounting Branch Chief Securities and Exchange Commission Washington , D.C. 20549 Re: Syneron Medical Ltd. Form 20-F for the Fiscal Year Ended December 31, 2011 Filed March 29, 2012 File No. 0-50867 Dear Mr. Vaughn: We enclose responses to the comments raised by the staff of the Securities and Exchange Commission (the “Staff”) in its comment letter,

August 27, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 23, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

August 27, 2012 EX-99.1

Syneron Announces Resignation of Chief Financial Officer Current Board Member and Former CEO/CFO David Schlachet to Serve as Interim CFO; Executive Search for Permanent Replacement Initiated

Syneron Announces Resignation of Chief Financial Officer Current Board Member and Former CEO/CFO David Schlachet to Serve as Interim CFO; Executive Search for Permanent Replacement Initiated YOKNEAM, Israel, Aug.

August 21, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 15, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate b

August 21, 2012 EX-99.1

Syneron Reports Second Quarter 2012 Results All time high revenue of $68.1 million, up 12% Year-Over-Year Non-GAAP net income of $1.9 million

EX-99.1 2 v322106ex99-1.htm EXHIBIT 99.1 Syneron Reports Second Quarter 2012 Results All time high revenue of $68.1 million, up 12% Year-Over-Year Non-GAAP net income of $1.9 million Yokneam, Israel, August 15, 2012 - Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, today announced second quarter 2012 financial results for the three month period ended June 30, 2012.

August 14, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 8, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

August 14, 2012 EX-99.1

Syneron to Present at the Canaccord Genuity Growth Conference

EX-99.1 2 v321385ex99-1.htm EXHIBIT 99.1 Syneron to Present at the Canaccord Genuity Growth Conference Yokneam, Israel, August 8, 2012 – Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, announced today that Louis P. Scafuri, Chief Executive Officer, is scheduled to present at the Canaccord Genuity Growth Conference in Boston. Conference: Canaccord Genuity Growth Con

August 2, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 1, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 25, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 25, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

July 2, 2012 6-K

Current Report of Foreign Issuer - FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 2, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 31, 2012 6-K

Current Report of Foreign Issuer - SYNERON MEDICAL LTD. 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 30, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 17, 2012 6-K

Current Report of Foreign Issuer - SYNERON MEDICAL LTD. 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 17, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by c

May 9, 2012 6-K

Current Report of Foreign Issuer - SYNERON MEDICAL LTD. 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 9, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by ch

April 30, 2012 6-K

Current Report of Foreign Issuer - SYNERON MEDICAL LTD. 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 24, 2012 Commission File Number: 000-50867 Syneron Medical Ltd. (Translation of registrant’s name into English) Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel (Address of principal executive offices) Indicate by

April 26, 2012 SC 13G

ELOS / Syneron Medical Ltd. / JPMORGAN CHASE & CO - SYNERON MEDICAL LTD. Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Syneron Medical Ltd.

April 16, 2012 SC 13G

ELOS / Syneron Medical Ltd. / Visium Asset Management, LP - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Syneron Medical Ltd (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) M87245102 (CUSIP Number) April 5, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Ru

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista